Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) vs CinnoVex in RRMS
NCT05242133Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Dec 2017
- Primary completion
- Apr 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon beta-1a in multiple sclerosis (MS), sponsored by CinnaGen. Started Dec 2017; status: completed.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05242133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242133.